.svg "CancerLinQ Logo Update 2025 (RGB)"){kind=small}
Manuscripts
Abstracts
June 3, 2022
The survival benefit of anti-HER2 treatment in the management of small (T1mic, T1a, T1b, T1c), node-negative HER2+ breast cancer
ASCO Annual Meeting 2022
Johnson K et al
June 3, 2022
Diagnosed with advanced prostate cancer: A population-based cohort from national oncology practices
ASCO Annual Meeting 2022
Kim SP et al
June 3, 2022
Characterizing node-negative non-small cell lung cancer patients with similarity networks: A CancerLinQ Discovery analysis
ASCO Annual Meeting 2022
Moen EL et al
June 3, 2022
Impact of trial site selection on minority patient recruitment in prostate cancer trials
ASCO Annual Meeting 2022
Lagor C et al
June 3, 2022
Identifying genetic factors of response and resistance to CDK4/6 inhibitors in metastatic HR+/HER2- breast cancer using real-world data
ASCO Annual Meeting 2022
Agrawal S et al
June 3, 2022
Evaluating the impact of performance status criteria on minority eligibility for oncology clinical trials
ASCO Annual Meeting 2022
Bhandari S et al
June 3, 2022
Machine learning modeling of real-world primary resistance and hyperprogression in immune checkpoint inhibitor (ICI) treated advanced non-small cell lung cancer (aNSCLC) patients
ASCO Annual Meeting 2022
Das R et al
June 3, 2022
Disparities in timely treatment among lung cancer patients
ASCO Annual Meeting 2022
Chhabra J et al
June 3, 2022
Comparison of DNA sequencing, immunohistochemistry, and in-situ hybridization techniques to determine HER2 status in metastatic breast cancer patients
ASCO Annual Meeting 2022
Lal LS et al
.svg "CancerLinQ Logo (White Cancer)"){kind=small}